Monograph
J07AL01 - Pneumococcus, Purified Polysaccharides Antigen |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the pneumococcus, purified polysaccharides antigen vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Purified polysaccharides antigen of 23 different serotypes.
Therapeutic characteristics
The pneumococcal vaccine is indicated for active immunization for the prevention of pneumococcal
disease caused by the 23 serotypes contained in the vaccine in persons over the age of 2, who are at increased risk for pneumococcal disease.
The vaccine can be injected subcutaneously or intramuscularly as a single dose.
Metabolism and pharmacokinetics
The pneumococcus vaccine is not metabolized by the cytochrome P450 system.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Pneumovax.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Serbia© NAPOS 2024